Abbrea Capital’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | $1.74M | Sell |
62,142
-4,520
| -7% | -$124K | 0.23% | 82 |
|
|
2024
Q1 | $1.85M | Sell |
66,662
-8,157
| -11% | -$226K | 0.24% | 81 |
|
|
2023
Q4 | $2.15M | Sell |
74,819
-14,250
| -16% | -$431K | 0.31% | 70 |
|
|
2023
Q3 | $2.95M | Sell |
89,069
-338
| -0.4% | -$12K | 0.47% | 48 |
|
|
2023
Q2 | $3.28M | Buy |
89,407
+466
| +0.5% | +$18.1K | 0.5% | 47 |
|
|
2023
Q1 | $3.63M | Sell |
88,941
-1,327
| -1% | -$57.3K | 0.62% | 39 |
|
|
2022
Q4 | $4.63M | Buy |
90,268
+1,560
| +2% | +$74.8K | 0.83% | 31 |
|
|
2022
Q3 | $3.88M | Sell |
88,708
-4,143
| -4% | -$201K | 0.73% | 35 |
|
|
2022
Q2 | $4.87M | Buy |
92,851
+114
| +0.1% | +$5.81K | 0.81% | 28 |
|
|
2022
Q1 | $4.8M | Buy |
92,737
+1,300
| +1% | +$67.5K | 0.67% | 37 |
|
|
2021
Q4 | $5.4M | Buy |
91,437
+360
| +0.4% | +$17.8K | 0.73% | 31 |
|
|
2021
Q3 | $3.92M | Buy |
91,077
+2,985
| +3% | +$132K | 0.58% | 36 |
|
|
2021
Q2 | $3.45M | Buy |
88,092
+7,406
| +9% | +$288K | 0.52% | 51 |
|
|
2021
Q1 | $2.92M | Buy |
80,686
+3,490
| +5% | +$124K | 0.48% | 53 |
|
|
2020
Q4 | $2.84M | Buy |
77,196
+39
| +0.1% | +$1.43K | 0.51% | 51 |
|
|
2020
Q3 | $2.69M | Buy |
77,157
+748
| +1% | +$26.2K | 0.57% | 45 |
|
|
2020
Q2 | $2.37M | Sell |
76,409
-906
| -1% | -$30.8K | 0.54% | 46 |
|
|
2020
Q1 | $2.39M | Sell |
77,315
-1,893
| -2% | -$64.5K | 0.64% | 45 |
|
|
2019
Q4 | $2.94M | Sell |
79,208
-2,619
| -3% | -$93.3K | 0.63% | 42 |
|
|
2019
Q3 | $2.79M | Sell |
81,827
-564
| -0.7% | -$20.5K | 0.65% | 43 |
|
|
2019
Q2 | $3.39M | Buy |
82,391
+12,635
| +18% | +$502K | 0.83% | 39 |
|
|
2019
Q1 | $2.81M | Buy |
69,756
+1,597
| +2% | +$64K | 0.81% | 38 |
|
|
2018
Q4 | $2.82M | Buy |
68,159
+3,354
| +5% | +$139K | 0.93% | 35 |
|
|
2018
Q3 | $2.71M | Sell |
64,805
-3,094
| -5% | -$119K | 0.8% | 38 |
|
|
2018
Q2 | $2.34M | Buy |
67,899
+1,343
| +2% | +$45.9K | 0.73% | 43 |
|
|
2018
Q1 | $2.24M | Buy |
66,556
+4,252
| +7% | +$146K | 0.73% | 42 |
|
|
2017
Q4 | $2.14M | Buy |
62,304
+5,643
| +10% | +$192K | 0.73% | 46 |
|
|
2017
Q3 | $1.92M | Buy |
56,661
+279
| +0.5% | +$8.97K | 0.71% | 45 |
|
|
2017
Q2 | $1.8M | Sell |
56,382
-1,546
| -3% | -$48.8K | 0.72% | 45 |
|
|
2017
Q1 | $1.88M | Sell |
57,928
-2,108
| -4% | -$66.5K | 0.77% | 43 |
|
|
2016
Q4 | $1.85M | Buy |
+60,036
| New | +$1.83M | 0.87% | 40 |
|
Other funds holding PFE
Abbrea Capital's PFE Position: Q2 2024 in Review
Abbrea Capital reduced its Pfizer (PFE) stake by 6.8% in Q2 2024, selling an estimated $124K and leaving 62,142 shares worth $1.74M. The position accounts for 0.23% of the portfolio, ranked #82.
Abbrea Capital first reported a position in PFE in Q4 2016 and has held it in 31 quarters since. The position peaked at $5.4M in Q4 2021. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.
- Abbrea Capital held 62,142 shares of Pfizer worth $1.74M as of Q2 2024.
- Abbrea Capital sold 4,520 Pfizer shares in Q2 2024, an estimated $124K.
- Pfizer made up 0.23% of Abbrea Capital's portfolio in Q2 2024, its #82 holding.
- Abbrea Capital first reported a position in Pfizer in Q4 2016 and has held it in 31 quarters since.
- Abbrea Capital's Pfizer position peaked at $5.4M in Q4 2021.
- 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.
Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.